Menu

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (37)

Company Market Cap Price
TMO Thermo Fisher Scientific Inc.
Thermo Fisher provides contract research organization services (CRO capabilities) for outsourced drug development.
$214.25B
$567.41
+2.01%
IQV IQVIA Holdings Inc.
IQVIA operates as outsourced drug development and clinical research services akin to a CRO.
$36.80B
$216.42
-0.02%
LH Labcorp Holdings Inc.
Labcorp functions as aContract Research Organization offering outsourced drug development and regulatory support services.
$21.10B
$253.95
+0.64%
MEDP Medpace Holdings, Inc.
Medpace's core business is a specialized full-service CRO delivering Phase I–IV clinical development services.
$16.43B
$584.01
+0.63%
ICLR ICON Public Limited Company
Directly describes ICON's outsourced drug development and management services as a Contract Research Organization.
$14.19B
$171.84
+3.93%
CRL Charles River Laboratories International, Inc.
CRL operates as a contract research organization, outsourcing preclinical drug development services.
$8.84B
$180.13
+0.57%
OLED Universal Display Corporation
Contract research services via Adesis subsidiary.
$7.00B
$147.12
+0.15%
RXRX Recursion Pharmaceuticals, Inc.
Collaborations with pharma partners and outsourced discovery work resemble a CRO-type service model.
$2.24B
$5.50
-2.65%
AZTA Azenta, Inc.
Genewiz genomic sequencing and broader SMS/Multiomics services align with Contract Research Organizations.
$1.38B
$30.21
+1.05%
FTRE Fortrea Holdings Inc.
Fortrea operates as a standalone contract research organization providing outsourced clinical development services.
$941.40M
$10.46
+4.24%
DNA Ginkgo Bioworks Holdings, Inc.
Contract Research Organizations as a historic and current service model.
$760.33M
$12.99
+8.16%
FLGT Fulgent Genetics, Inc.
Contract Research Organization services for bioPharma.
$683.46M
$22.44
-0.62%
CLPT ClearPoint Neuro, Inc.
Biologics and drug-delivery consulting capabilities (GLP expansion, preclinical support) align with CRO-like outsourced development services.
$649.91M
$23.23
-1.92%
ABSI Absci Corporation
Partnership-driven model for drug creation aligns with Contract Research Organizations (CRO)-like outsourced R&D services.
$545.95M
$4.29
+4.77%
ACRS Aclaris Therapeutics, Inc.
The company reports contract research revenue, indicating provided drug development services.
$272.87M
$2.52
+1.20%
LFCR Lifecore Biomedical, Inc.
Lifecore's development pipeline and development services align with Contract Research Organizations.
$266.21M
$7.18
+1.13%
IMRX Immuneering Corporation
The company relies on contract research organizations for preclinical/clinical testing and trials.
$247.22M
$6.88
+7.25%
QTRX Quanterix Corporation
Offers contract research services via its Accelerator Lab, aligning with CRO-type activities.
$207.35M
$5.34
+6.90%
MXCT MaxCyte, Inc.
Contract Research Organizations tag reflects MaxCyte's CRO-like gene editing assessment services through SeQure Dx.
$163.73M
$1.53
+1.66%
BNR Burning Rock Biotech Limited
Biopharma services segment indicates outsourced R&D, clinical testing, and development support.
$138.94M
$13.56
+9.44%
CSBR Champions Oncology, Inc.
Company provides outsourced drug development and preclinical/clinical research services to biopharma (CRO-style).
$94.24M
$6.84
+0.44%
FBIO Fortress Biotech, Inc.
Fortress engages in outsourced development activities and governance across its portfolio, aligning with CRO services.
$75.70M
$2.56
-0.19%
AKYA Akoya Biosciences, Inc.
Contract Research Organizations alignment due to outsourced lab services and clinical testing capabilities.
$64.26M
$1.29
CBUS Cibus, Inc.
Reported contract research revenue indicates direct R&D services provided to clients alongside platform licensing.
$55.02M
$1.59
+3.25%
BDSX Biodesix, Inc.
Biodesix's Development Services revenue aligns with CRO-like outsourced diagnostic testing for partners.
$50.05M
$6.98
+6.24%
ABVC ABVC BioPharma, Inc.
BioKey provides Contract Research Organization services, including API characterization, formulation development, and regulatory submissions.
$46.97M
$2.77
-1.77%
NOTV Inotiv, Inc.
Inotiv operates as a CRO delivering nonclinical drug discovery and development services, aligning with the Contract Research Organizations tag.
$45.69M
$1.34
+0.75%
VNRX VolitionRx Limited
Nu.Q Discover provides epigenetic profiling services to drug developers, akin to Contract Research Organizations.
$44.71M
$0.43
-1.68%
RADX Radiopharm Theranostics Limited
Company provides external development services for others, akin to CRO activities.
$34.73M
$5.30
+2.51%
PLUR Pluri Inc.
Contract research and development services complement CDMO capabilities and scale the pipeline.
$30.55M
$3.99
+2.57%
BFRG Bullfrog AI Holdings, Inc. Common Stock
Engages in external collaborations/partnerships to provide AI-driven drug development services, akin to CRO-type engagements.
$12.05M
$1.27
-0.39%
SEED Origin Agritech Limited
Origin provides breeding services and collaborative R&D through a service consortium, aligning with Contract Research Organizations.
$10.71M
$1.72
+2.08%
APM Aptorum Group Limited
Aptorum plans near-term revenue from biopharma services via the DiamiR merger, aligning with contract research/Development outsourcing.
$7.88M
$1.45
-1.70%
BUDZ WEED, Inc.
Sangre AgroTech represents plant genomic research services, akin to contract research and development.
$5.44M
$0.04
POAI Predictive Oncology Inc.
Provides outsourced drug discovery services (wet lab, testing, and preclinical support) akin to a CRO.
$5.31M
$8.78
+3.72%
ELAB PMGC Holdings Inc.
Contract Research Organizations (CRO)-like R&D capabilities through PMGC Research Inc. for biotech development.
$2.33M
$5.87
-2.74%
YBGJ Yubo International Biotech Limited
Provides outsourced research/testing services and advisory functions (CRO-like capabilities).
$2.32M
$0.01

Loading company comparison...

Loading research report...

APM Aptorum Group Limited

Aptorum Group Reports Fiscal Year 2024 Financial Results

Nov 01, 2025
IQV IQVIA Holdings Inc.

IQVIA Beats Q3 2025 Earnings, Exceeds Revenue and EPS Expectations

Oct 28, 2025
LH Labcorp Holdings Inc.

Labcorp Reports Q3 2025 Earnings, Raises Full‑Year Guidance

Oct 28, 2025
CRL Charles River Laboratories International, Inc.

Charles River Laboratories Announces ADC Development Collaboration with Francis Crick Institute

Oct 24, 2025
ICLR ICON Public Limited Company

ICON Reports Third Quarter 2025 Results

Oct 23, 2025
MEDP Medpace Holdings, Inc.

Medpace Holdings Reports Q3 2025 Earnings, Beats Estimates, Raises 2025 Guidance

Oct 23, 2025
APM Aptorum Group Limited

Aptorum Group Announces Up To $6 Million Registered Direct Offering

Oct 10, 2025
LH Labcorp Holdings Inc.

Labcorp Declares Quarterly Dividend of $0.72 per Share

Oct 10, 2025
APM Aptorum Group Limited

Aptorum Group Announces Board and Management Expansion Post-Merger with DiamiR Biosciences

Oct 09, 2025
IQV IQVIA Holdings Inc.

IQVIA and GSK Expand Vaccine Track Data Tool with Enhanced Local Coverage and Historical Insights

Oct 01, 2025
IQV IQVIA Holdings Inc.

IQVIA Receives WCG Pinnacle Award for Excellence in Site Relationships

Sep 16, 2025
CSBR Champions Oncology, Inc.

Champions Oncology Reports Q1 Fiscal 2026 Results with $14.0 Million Revenue and Loss Per Share

Sep 15, 2025
IQV IQVIA Holdings Inc.

IQVIA Launches Clinical Trial Financial Suite, an AI-Enabled Platform for Integrated Financial Management

Sep 10, 2025
IQV IQVIA Holdings Inc.

Jefferies Upgrades IQVIA Holdings to Buy Rating

Sep 09, 2025
IQV IQVIA Holdings Inc.

IQVIA Announces CFO Transition: Michael Fedock to Succeed Ron Bruehlman in Early 2026

Sep 02, 2025
IQV IQVIA Holdings Inc.

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate Life Sciences Companies

Aug 28, 2025
APM Aptorum Group Limited

DiamiR Biosciences Receives New York State Approval for APOE Genotyping Test

Aug 21, 2025
IQV IQVIA Holdings Inc.

IQVIA and Veeva Systems Resolve Disputes, Announce Long-Term Clinical and Commercial Partnerships

Aug 18, 2025
IQV IQVIA Holdings Inc.

IQVIA Holdings Partners with Kexing Biopharm to Enhance Global Drug Development

Aug 12, 2025
APM Aptorum Group Limited

Aptorum Group Regains Compliance with NASDAQ Minimum Bid Price Requirement

Aug 04, 2025
CSBR Champions Oncology, Inc.

Champions Oncology Reports Record Annual Revenue of $57 Million, Returns to Profitability in Fiscal Year 2025

Jul 23, 2025
IQV IQVIA Holdings Inc.

IQVIA Beats Q2 Estimates, Updates 2025 Revenue Guidance, and Completes Share Buyback

Jul 22, 2025
CSBR Champions Oncology, Inc.

Champions Oncology Appoints Rob Brainin as New Chief Executive Officer

Jul 18, 2025
APM Aptorum Group Limited

Aptorum Group and DiamiR Biosciences Announce Definitive Merger Agreement

Jul 16, 2025
CSBR Champions Oncology, Inc.

Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License

Jul 08, 2025
IQV IQVIA Holdings Inc.

IQVIA Holdings Dropped from Russell Growth Indices

Jun 30, 2025
IQV IQVIA Holdings Inc.

IQVIA Health Research Space Wins MedTech Breakthrough Award for 'Best Mobile App for Patient Engagement'

Jun 16, 2025
IQV IQVIA Holdings Inc.

IQVIA Launches New AI Agents for Life Sciences and Healthcare with NVIDIA Technology

Jun 11, 2025
IQV IQVIA Holdings Inc.

IQVIA Announces Pricing of $2 Billion Senior Notes Due 2032

May 30, 2025
IQV IQVIA Holdings Inc.

Rein Therapeutics Doses First Patient in Phase 2 Trial, Collaborating with IQVIA for Enrollment

May 27, 2025
IQV IQVIA Holdings Inc.

IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials

May 16, 2025
IQV IQVIA Holdings Inc.

IQVIA Reports Strong Q1 2025 Results, Raises Full-Year Revenue Guidance

May 06, 2025
CSBR Champions Oncology, Inc.

Champions Oncology Obtains Radioactive Materials License, Expands Radiotherapeutic Study Capabilities

Apr 28, 2025
CSBR Champions Oncology, Inc.

Champions Oncology Forms Strategic Collaboration with Turbine to Advance Data Platform

Apr 24, 2025
IQV IQVIA Holdings Inc.

IQVIA Named 'Front-Runner Generative AI Leader' by Everest Group for Life Sciences

Apr 23, 2025
APM Aptorum Group Limited

Aptorum Group Receives Nasdaq Minimum Bid Price Deficiency Notification

Apr 16, 2025
IQV IQVIA Holdings Inc.

IQVIA Institute Report: Biopharma R&D Metrics Show Stabilization and Improvement in 2024

Apr 15, 2025
CSBR Champions Oncology, Inc.

Champions Oncology Achieves Record Q3 Fiscal 2025 Revenue and Net Income, Secures First Major Data Licensing Deal

Mar 11, 2025
IQV IQVIA Holdings Inc.

IQVIA Holdings Secures Loan Refinancing, Reduces Interest Rate by 0.25% Points

Mar 11, 2025
IQV IQVIA Holdings Inc.

IQVIA Recognized as a Leader in IDC MarketScape for Decentralized Clinical Trial Technologies

Mar 10, 2025
IQV IQVIA Holdings Inc.

IQVIA Laboratories Launches Site Lab Navigator to Streamline Clinical Trial Workflows

Mar 04, 2025
IQV IQVIA Holdings Inc.

IQVIA Institute Report: Restrictive Pharmacist Policies Lead to Millions of Missed Adult Vaccinations

Feb 25, 2025
IQV IQVIA Holdings Inc.

IQVIA AI Assistant Wins 2024 PM360 Innovation Award for Artificial Intelligence

Feb 24, 2025
IQV IQVIA Holdings Inc.

IQVIA Releases 2024 Sustainability Report Highlighting Innovation and Collaboration

Feb 20, 2025
CSBR Champions Oncology, Inc.

Champions Oncology to Present 17 Abstracts at 2025 AACR Annual Meeting

Feb 18, 2025
IQV IQVIA Holdings Inc.

IQVIA Beats Q4 Estimates, Reaffirms 2025 Guidance, and Increases Share Repurchase Authorization

Feb 06, 2025
IQV IQVIA Holdings Inc.

IQVIA Named No. 1 in Sector on Fortune World's Most Admired Companies List for Fourth Consecutive Year

Feb 04, 2025
IQV IQVIA Holdings Inc.

IQVIA Institute Report Highlights Future Opportunities and Gaps in Biosimilar Market

Jan 31, 2025
IQV IQVIA Holdings Inc.

IQVIA and NVIDIA Partner to Advance Healthcare and Life Sciences with Agentic AI

Jan 13, 2025
CSBR Champions Oncology, Inc.

Champions Oncology Expands Bioanalytical Services with Cytek Aurora Flow Cytometers and New Leadership

Jan 08, 2025

The most compelling investment themes are the ones nobody is talking about yet.

Every Monday, get three under-the-radar themes with catalysts, data, and stocks poised to benefit.

Sign up now to receive them!

Also explore our analysis on 5,000+ stocks